Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction.
暂无分享,去创建一个
J. Ferrières | N. Danchin | T. Simon | Y. Cottin | L. Lorgis | F. Leclercq | A. Vahanian | J. Berland | P. Guéret | D. Simon | M. Zeller | V. Bataille | J. Machecourt | J. Cambou | G. Mulak | R. Deturck | X. Tabone | E. Drouet | P. Wyart | P. Guéret
[1] S. Schinner. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes , 2009 .
[2] O. Pedersen,et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. , 2008, The New England journal of medicine.
[3] L. Rydén,et al. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. , 2007, European heart journal.
[4] D. Balzi,et al. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer‐related mortality , 2007, Diabetes/metabolism research and reviews.
[5] N. Danchin,et al. The French registry of Acute ST elevation or non-ST-elevation Myocardial Infarction (FAST-MI): study design and baseline characteristics. , 2007, Archives des maladies du coeur et des vaisseaux.
[6] N. Marchionni,et al. Three‐year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin , 2006, Diabetes/metabolism research and reviews.
[7] J. Rungby,et al. Sulfonylureas and the risk of myocardial infarction. , 2006, Metabolism: clinical and experimental.
[8] H. Sørensen,et al. Risk and Short-Term Prognosis of Myocardial Infarction Among Users of Antidiabetic Drugs , 2006, American journal of therapeutics.
[9] J. Muller,et al. Effect of diabetes mellitus and its treatment on ventricular arrhythmias complicating acute myocardial infarction , 2005, Diabetic medicine : a journal of the British Diabetic Association.
[10] G. Charpentier,et al. Role of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registry , 2005, Diabetes/metabolism research and reviews.
[11] D. Yellon,et al. Myocardial Protection from Either Ischaemic Preconditioning or Nicorandil Is Not Blocked by Gliclazide , 2004, Cardiovascular Drugs and Therapy.
[12] M. Nauck,et al. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important? , 2003, Heart.
[13] S. Behar,et al. Sulfonylureas Are Not Associated With Increased Mortality in Diabetics Treated With Thrombolysis for Acute Myocardial Infarction , 2001, Journal of Thrombosis and Thrombolysis.
[14] Á. Avezum,et al. Predictors of hospital mortality in the global registry of acute coronary events. , 2003, Archives of internal medicine.
[15] J. Huizar,et al. Sulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetics. , 2003, Journal of the American College of Cardiology.
[16] J P Riveline,et al. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications. , 2003, Diabetes & metabolism.
[17] M. Riddle. Editorial: sulfonylureas differ in effects on ischemic preconditioning--is it time to retire glyburide? , 2003, The Journal of clinical endocrinology and metabolism.
[18] T. Reffelmann,et al. Post-stenotic coronary blood flow at rest is not altered by therapeutic doses of the oral antidiabetic drug glibenclamide in patients with coronary artery disease , 2002, Heart.
[19] W. Aronow,et al. Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone. , 2001, The American journal of cardiology.
[20] F. Ashcroft,et al. Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells , 2001, Diabetologia.
[21] N. Standen,et al. Glimepiride, a Novel Sulfonylurea, Does Not Abolish Myocardial Protection Afforded by Either Ischemic Preconditioning or Diazoxide , 2001, Circulation.
[22] W. Schmiegel,et al. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide) , 2000, European heart journal.
[23] S. Smith,et al. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. , 1999, American heart journal.
[24] W. Burger,et al. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. , 1999, European heart journal.
[25] A. Terzic,et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. , 1999, Journal of the American College of Cardiology.
[26] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[27] Uk-Prospective-Diabetes-Study-Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.
[28] A. Terzic,et al. The sulfonylurea controversy: more questions from the heart. , 1998, Journal of the American College of Cardiology.
[29] A. Terzic,et al. Sulfonylureas and mortality in diabetic patients after myocardial infarction. , 1998, Circulation.
[30] A. Harken,et al. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. , 1997, Circulation.
[31] K. Malmberg. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus , 1997, BMJ.
[32] D. Yellon,et al. Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. , 1996, Circulation.
[33] M. Varricchio,et al. Effectiveness of glibenclamide on myocardial ischemic ventricular arrhythmias in non-insulin-dependent diabetes mellitus. , 1991, The American journal of cardiology.
[34] H. Seltzer. A Summary of Criticisms of the Findings and Conclusions of the University Group Diabetes Program (UGDP) , 1972, Diabetes.